DK2970493T3 - Fremgangsmåder til opnåelse af terapeutisk effektive doser af anti-cd47-midler - Google Patents
Fremgangsmåder til opnåelse af terapeutisk effektive doser af anti-cd47-midler Download PDFInfo
- Publication number
- DK2970493T3 DK2970493T3 DK14768797.4T DK14768797T DK2970493T3 DK 2970493 T3 DK2970493 T3 DK 2970493T3 DK 14768797 T DK14768797 T DK 14768797T DK 2970493 T3 DK2970493 T3 DK 2970493T3
- Authority
- DK
- Denmark
- Prior art keywords
- retiring
- procedures
- efficient dosage
- therapeutic
- therapeutic efficient
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800102P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/018743 WO2014149477A1 (en) | 2013-03-15 | 2014-02-26 | Methods for achieving therapeutically effective doses of anti-cd47 agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2970493T3 true DK2970493T3 (da) | 2019-05-13 |
Family
ID=51580621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14768797.4T DK2970493T3 (da) | 2013-03-15 | 2014-02-26 | Fremgangsmåder til opnåelse af terapeutisk effektive doser af anti-cd47-midler |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US9623079B2 (da) |
| EP (3) | EP2970493B1 (da) |
| JP (5) | JP6426693B2 (da) |
| CN (3) | CN114917336A (da) |
| AU (4) | AU2014238105B2 (da) |
| CA (1) | CA2903773A1 (da) |
| DK (1) | DK2970493T3 (da) |
| ES (1) | ES2728066T3 (da) |
| HK (1) | HK1219956A1 (da) |
| IL (1) | IL241347B (da) |
| PT (1) | PT2970493T (da) |
| WO (1) | WO2014149477A1 (da) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050958T2 (hu) | 2008-01-15 | 2021-01-28 | Univ Leland Stanford Junior | Akut mieloid leukémia õssejtek markerei |
| US11072655B2 (en) * | 2008-01-15 | 2021-07-27 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| AU2013359167B2 (en) | 2012-12-12 | 2018-08-23 | Arch Oncology, Inc. | Therapeutic CD47 antibodies |
| US9221908B2 (en) | 2012-12-12 | 2015-12-29 | Vasculox, Inc. | Therapeutic CD47 antibodies |
| EP2970493B1 (en) | 2013-03-15 | 2019-04-03 | The Board of Trustees of the Leland Stanford Junior University | Methods for achieving therapeutically effective doses of anti-cd47 agents |
| ES2765483T3 (es) | 2013-09-18 | 2020-06-09 | Univ Leland Stanford Junior | Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica |
| WO2016065245A1 (en) * | 2014-10-24 | 2016-04-28 | Incept, Llc | Extra luminal scaffold |
| RU2576614C1 (ru) * | 2015-01-19 | 2016-03-10 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "33 ЦЕНТРАЛЬНЫЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИСПЫТАТЕЛЬНЫЙ ИНСТИТУТ" Минобороны России | Способ поиска точки с дробным эффектом при определении эффективных доз веществ методом "одной точки" |
| ES2761861T3 (es) * | 2015-01-21 | 2020-05-21 | Univ Leland Stanford Junior | Uso de agonistas de TLR y agente anti-CD47 para mejorar la fagocitosis de las células cancerosas |
| ES2838925T3 (es) * | 2015-02-27 | 2021-07-02 | Univ Leland Stanford Junior | Terapia de combinación para el tratamiento de la ateroesclerosis |
| GEP20217326B (en) | 2015-08-07 | 2021-11-25 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| CA2998644A1 (en) | 2015-09-18 | 2017-03-23 | Arch Oncology, Inc. | Therapeutic cd47 antibodies |
| AU2016326423A1 (en) | 2015-09-21 | 2018-04-26 | Erasmus University Medical Center | Anti-CD47 antibodies and methods of use |
| WO2017100462A2 (en) * | 2015-12-11 | 2017-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of cd47 and egfr |
| SG11201806110QA (en) * | 2016-01-21 | 2018-08-30 | Univ Leland Stanford Junior | Treatment of cancer with combinations of immunoregulatory agents |
| JP7532009B2 (ja) * | 2016-04-15 | 2024-08-13 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | がん処置における抗ｃｄ４７薬の治療有効用量を決定及び達成する方法 |
| US9957576B2 (en) | 2016-04-21 | 2018-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for determining responsiveness to an anti-CD47 agent |
| SI3448421T1 (sl) | 2016-04-29 | 2022-02-28 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | Postopki in sestavki za preprečevanje in zdravljenje kirurških adhezij |
| CN117717604A (zh) | 2016-07-19 | 2024-03-19 | 梯瓦制药澳大利亚股份有限公司 | 抗cd47联合治疗 |
| JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| WO2018081448A1 (en) | 2016-10-26 | 2018-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| CA3053392A1 (en) | 2017-02-28 | 2018-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Antifibrotic activity of cd47 blockade |
| US11078272B2 (en) | 2017-03-09 | 2021-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of CD47 pathway |
| SI3642242T1 (sl) * | 2017-06-21 | 2024-05-31 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | Parametri odmerjanja za terapije, ki ciljajo na CD47, za hematološke malignosti |
| BR112020001679A2 (pt) | 2017-08-02 | 2020-07-21 | Phanes Therapeutics, Inc. | anticorpos anti-cd47 e usos dos mesmos |
| CN111315783A (zh) | 2017-10-18 | 2020-06-19 | 四十七公司 | 用抗cd47和抗pd-l1治疗卵巢癌 |
| PT3697817T (pt) | 2017-10-18 | 2023-01-02 | Forty Seven Inc | Terapia contra o cancro do ovário à base de agente anti-cd47 |
| EA202091339A1 (ru) | 2017-12-01 | 2020-10-21 | Сиэтл Дженетикс, Инк. | Антитела против cd47 и их применение для лечения онкологических заболеваний |
| ES2927305T3 (es) * | 2018-02-12 | 2022-11-04 | Forty Seven Inc | Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20 |
| KR20200133376A (ko) | 2018-03-21 | 2020-11-27 | 알렉소 온콜로지 인크. | 신호-조절 단백질 알파에 대한 항체 및 사용 방법 |
| US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
| TW202028237A (zh) | 2018-09-27 | 2020-08-01 | 美商西建公司 | SIRPα結合蛋白及其使用方法 |
| WO2020163692A1 (en) * | 2019-02-08 | 2020-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cutaneous t cell lymphoma with targeting of cd47 pathway |
| CN113906049A (zh) * | 2019-05-24 | 2022-01-07 | 四十七公司 | 用于共施用针对c-kit和CD47的免疫治疗剂的方案 |
| JP2022534212A (ja) | 2019-05-31 | 2022-07-28 | エーエルエックス オンコロジー インコーポレイテッド | 免疫チェックポイント阻害剤と組み合わせてｓｉｒｐアルファｆｃ融合によりがんを治療する方法 |
| MA56119A (fr) | 2019-06-07 | 2022-04-13 | Alx Oncology Inc | Procédés et réactifs pour réduire les interférences de médicaments se liant au cd47 dans des dosages sérologiques |
| EP4045083B1 (en) | 2019-10-18 | 2024-01-10 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| WO2021124073A1 (en) | 2019-12-17 | 2021-06-24 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
| WO2022130016A1 (en) | 2020-12-18 | 2022-06-23 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| US12098214B2 (en) | 2021-05-13 | 2024-09-24 | ALX Oncology Inc. | Combination therapies for treating cancer |
| WO2023009189A1 (en) * | 2021-07-28 | 2023-02-02 | Actinium Pharmaceuticals, Inc. | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer |
| KR20240099484A (ko) | 2021-11-19 | 2024-06-28 | 한국과학기술연구원 | 표적 세포로의 활성 제약 성분의 적혈구-매개 전달을 위한 치료 화합물 |
| WO2023133577A1 (en) * | 2022-01-10 | 2023-07-13 | Kiniksa Pharmaceuticals, Ltd. | Methods of treating or reducing risk of transplant rejection |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| WO2024105180A1 (en) | 2022-11-16 | 2024-05-23 | Boehringer Ingelheim International Gmbh | Predictive efficacy biomarkers for anti-sirpa antibodies |
| WO2024121777A1 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| WO2002092784A2 (en) * | 2001-05-15 | 2002-11-21 | Emory University | POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47 |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| WO2007033221A2 (en) | 2005-09-13 | 2007-03-22 | The General Hospital Corporation | Methods and compositions for inhibition of immune responses |
| US8377448B2 (en) | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP2388270A3 (en) | 2007-10-11 | 2012-04-25 | The Hospital For Sick Children | Modulation of SIRPa - CD47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| CN101456911A (zh) | 2007-12-12 | 2009-06-17 | 江苏豪森药业股份有限公司 | 促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途 |
| ES2582340T3 (es) | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos para manipular fagocitosis mediada por CD47 |
| HUE050958T2 (hu) | 2008-01-15 | 2021-01-28 | Univ Leland Stanford Junior | Akut mieloid leukémia õssejtek markerei |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| PL2477648T3 (pl) | 2009-09-15 | 2022-11-07 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistyczna terapia anty-cd47 dla nowotworów hematologicznych |
| WO2011041453A1 (en) * | 2009-09-29 | 2011-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation and use of melanoma cancer stem cells |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| ES2816647T3 (es) * | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| US20140140989A1 (en) * | 2012-02-06 | 2014-05-22 | Inhibrx Llc | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof |
| ES2743203T3 (es) * | 2012-02-06 | 2020-02-18 | Inhibrx Inc | Anticuerpos CD47 y métodos de uso de los mismos |
| SG11201408646VA (en) | 2012-07-06 | 2015-01-29 | Genmab Bv | Dimeric protein with triple mutations |
| EP2953643B1 (en) * | 2013-02-06 | 2023-02-22 | Inhibrx, Inc. | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
| EP2970493B1 (en) | 2013-03-15 | 2019-04-03 | The Board of Trustees of the Leland Stanford Junior University | Methods for achieving therapeutically effective doses of anti-cd47 agents |
-
2014
- 2014-02-26 EP EP14768797.4A patent/EP2970493B1/en active Active
- 2014-02-26 DK DK14768797.4T patent/DK2970493T3/da active
- 2014-02-26 CA CA2903773A patent/CA2903773A1/en active Pending
- 2014-02-26 ES ES14768797T patent/ES2728066T3/es active Active
- 2014-02-26 PT PT14768797T patent/PT2970493T/pt unknown
- 2014-02-26 CN CN202210327266.1A patent/CN114917336A/zh active Pending
- 2014-02-26 CN CN201480015159.9A patent/CN105189556A/zh active Pending
- 2014-02-26 WO PCT/US2014/018743 patent/WO2014149477A1/en active Application Filing
- 2014-02-26 AU AU2014238105A patent/AU2014238105B2/en active Active
- 2014-02-26 EP EP20201319.9A patent/EP3792285A1/en active Pending
- 2014-02-26 EP EP19166334.3A patent/EP3536709A1/en active Pending
- 2014-02-26 CN CN202010960541.4A patent/CN112245586A/zh active Pending
- 2014-02-26 JP JP2016500441A patent/JP6426693B2/ja active Active
- 2014-02-26 US US14/769,069 patent/US9623079B2/en active Active
-
2015
- 2015-09-09 IL IL241347A patent/IL241347B/en active IP Right Grant
-
2016
- 2016-07-06 HK HK16107912.2A patent/HK1219956A1/zh unknown
-
2017
- 2017-02-02 US US15/423,325 patent/US10301387B2/en active Active
-
2018
- 2018-10-25 JP JP2018201216A patent/JP6704974B2/ja active Active
-
2019
- 2019-01-17 AU AU2019200294A patent/AU2019200294B2/en active Active
- 2019-04-04 US US16/375,238 patent/US11104731B2/en active Active
-
2020
- 2020-05-13 JP JP2020084674A patent/JP7007422B2/ja active Active
- 2020-11-17 AU AU2020270485A patent/AU2020270485B2/en active Active
- 2020-11-23 US US17/102,183 patent/US11136391B2/en active Active
-
2021
- 2021-08-12 US US17/401,046 patent/US20210380689A1/en active Pending
-
2022
- 2022-01-06 JP JP2022001223A patent/JP7246528B2/ja active Active
- 2022-05-02 US US17/734,904 patent/US11603404B2/en active Active
- 2022-05-02 US US17/734,949 patent/US11518806B2/en active Active
-
2023
- 2023-02-03 US US18/164,252 patent/US20230303688A1/en active Pending
- 2023-03-14 JP JP2023039709A patent/JP7562736B2/ja active Active
-
2024
- 2024-08-20 AU AU2024210996A patent/AU2024210996A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2970493T3 (da) | Fremgangsmåder til opnåelse af terapeutisk effektive doser af anti-cd47-midler | |
| DK2968071T3 (da) | Enhed til oral levering af terapeutiske forbindelser | |
| DK3030323T3 (da) | Kdm1a-inhibitorer til behandlingen af sygdom | |
| DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
| DK3329884T3 (da) | Implanterbar indretning til behandling af glaukom | |
| DK3218828T3 (da) | Dataindsamling til dosering af lægemidler | |
| DK3391918T3 (da) | Engangs-afgivelsesenhed til medicinafgivelsesanordning | |
| DK3057628T3 (da) | Injektionsindretning til terapeutisk middel | |
| DK2968208T3 (da) | Behandling af kataplexi | |
| DK2958900T3 (da) | 2-aminopyrimidinderivater til behandling af virusinfektioner | |
| DK2954051T3 (da) | Modificeret kapsid til genoverførsel til behandling af nethinden | |
| DK2964315T3 (da) | System til behandling af neuromotorisk dysfunktion | |
| DK3033086T3 (da) | Kombinationsterapi til behandling af cancer | |
| DK3023100T3 (da) | Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer | |
| BR112016009485A2 (pt) | Inalador de medicamento | |
| DK2961388T3 (da) | Kombinationer af lægemidler | |
| DK2970389T3 (da) | Farmaceutiske forbindelser | |
| DK2981255T3 (da) | Terapeutiske anvendelser af empagliflozin | |
| DK3076976T3 (da) | Fremgangsmåder til behandling af cancer | |
| DK3021838T3 (da) | Behandling af fedme | |
| DK2844279T3 (da) | Doseringsprogrammer til behandling af pompes sygdom | |
| DK2764881T3 (da) | System til medicinsk behandling | |
| DK3007726T3 (da) | Fremgangsmåder til behandling af en tauopati | |
| DK3016493T3 (da) | Behandling til desinficering af frø | |
| DK2767269T3 (da) | Terapeutisk anordning |